Breaking News, Collaborations & Alliances

Mapi Pharma, Mylan Expand MS Alliance

Mylan to invest an additional $20M in Mapi to support progress in Phase III trials of once-monthly Glatiramer Acetate Depot for RRMS

By: Contract Pharma

Contract Pharma Staff

Mapi Pharma Ltd. received an additional $20 million investment from Mylan to support Phase III clinical study progress to bring Glatiramer Acetate (GA) Depot, a once-monthly injection for the treatment of relapsing-remitting multiple sclerosis (RRMS), to market in the U.S. Mapi initiated the Phase III study in October and is a 1,000 patient pivotal clinical study designed to support a New Drug Application (NDA) with the FDA. Mapi is also building capacity at its facility to supply GA-Depot f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters